LGND Technical Analysis & Stock Price Forecast
This article provides a technical analysis of Ligand Pharmaceuticals Inc (LGND), indicating a "Sell" consensus based on various indicators. It details the stock's performance relative to moving averages, its RSI, MACD readings, and key support and resistance levels. The analysis aggregates 10 technical signals, showing more sell indicators than buy indicators as of April 2, 2026.
Vanguard (LGND) reports 0 shares after internal realignment (03/27/2026)
The Vanguard Group filed an amended Schedule 13G/A report for Ligand Pharmaceuticals Inc. (LGND), stating it now beneficially owns 0 shares and 0% of the common stock. This change is due to an internal realignment within Vanguard, where certain subsidiaries will now report their holdings separately, as per SEC Release No. 34-39538. This filing reflects an administrative change rather than a sale or purchase of stock.
Clark Capital Management Group Inc. Acquires 11,858 Shares of Ligand Pharmaceuticals Incorporated $LGND
Clark Capital Management Group Inc. increased its stake in Ligand Pharmaceuticals Incorporated by 16.7% in the third quarter, purchasing an additional 11,858 shares. This acquisition brings their total holdings to 82,991 shares, valued at $14.7 million. Other institutional investors also significantly boosted their positions in Ligand Pharmaceuticals, while company insiders recently sold shares totaling millions.
Russell Investments Group Ltd. Sells 9,403 Shares of Ligand Pharmaceuticals Incorporated $LGND
Russell Investments Group Ltd. has reduced its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 6.5% during the third quarter, selling 9,403 shares and now holding 136,130 shares valued at $24.1 million. Despite insider selling, analysts maintain a "Moderate Buy" rating with an average target price of $245, following the company beating earnings expectations and providing strong FY2026 guidance. Institutional investors collectively own over 91% of Ligand Pharmaceuticals.
Bofa Global Research announced that it has initiated coverage of Ligand Pharmaceuticals Inc. for the first time, assigning it a "Buy" rating.
Bofa Global Research has initiated coverage of Ligand Pharmaceuticals Inc. with a "Buy" rating and set a target stock price of $244 for the biopharmaceutical company. The article cites this as new coverage for Ligand Pharmaceuticals.
Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says
Bank of America has initiated coverage of Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy rating and a $244 price target, highlighting the company's royalty-focused business model and diversified portfolio. Ligand's strategy of providing capital and technology to drug developers in exchange for royalties allows it to generate high-margin returns with reduced risk in the biopharma sector. The company's strong EPS growth, disciplined deal-making, and technology platforms like Captisol are key drivers for its projected 23% CAGR in royalty receipts through 2030.
Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says
Bank of America has initiated coverage of Ligand Pharmaceuticals Inc (NASDAQ:LGND) with a Buy rating and a $244 price target, highlighting the company's royalty-focused business model and diversified portfolio. The firm believes Ligand's strategy of providing capital and technology in exchange for royalties allows it to deliver diversified, high-margin returns and continued EPS growth for investors seeking biopharma exposure with lower risk. The report also pointed to Ligand's strong investment team and its Captisol drug formulation technology as additional drivers for future growth and potential multiple expansion.
LIGAND PHARMACEUTICALS INC SEC 10-K Report
Ligand Pharmaceuticals Inc. has released its 2025 10-K report, highlighting significant financial growth with total revenue of $268.1 million and a net income of $124.5 million. The biopharmaceutical royalty aggregator operates with a lean model, focusing on acquiring and managing royalty interests in various biopharmaceutical products, including key assets like Kyprolis and Filspari. While demonstrating robust performance and strategic advancements like the Pelthos Transaction and new financing, the company also acknowledges operational, intellectual property, regulatory, and financial risks inherent in its business model.
Vanguard Group Inc. Has $367.79 Million Stake in Ligand Pharmaceuticals Incorporated $LGND
Vanguard Group Inc. decreased its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 0.6% in the third quarter, yet still holds 10.59% of the company, valued at $367.79 million. Ligand Pharmaceuticals recently exceeded Q4 earnings and revenue expectations and provided strong FY2026 adjusted EPS guidance, projecting substantial growth in royalty revenue through 2030. Despite insider selling and some investor uncertainty regarding revenue guidance, analysts largely maintain a "Moderate Buy" rating for the stock.
Ligand Pharmaceuticals (NasdaqGM:LGND) Stock Price
This article provides an analysis of Ligand Pharmaceuticals (NasdaqGM:LGND), highlighting its stock performance, fair value, and financial metrics. It details the company's diverse royalty partnerships and asset-light acquisitions as key drivers for strengthening its global healthcare reach, boosting recurring revenue, and supporting future earnings. The report also includes recent news, key financial details, and comparisons with competitors.
Aberdeen Group plc Has $33.61 Million Stock Position in Ligand Pharmaceuticals Incorporated $LGND
Aberdeen Group plc reduced its stake in Ligand Pharmaceuticals by 17.2% in Q3, owning 189,748 shares valued at $33.61 million. Institutional investors collectively own 91.28% of the stock, while company insiders have sold 3,205 shares worth $611,192 in the last quarter. Analysts maintain a "Moderate Buy" consensus with an average price target of $239.33.
Ligand Pharmaceuticals Announces Fourth Quarter and Full Year 2025 Financial Results Call Scheduled for February 26, 2026
Ligand Pharmaceuticals (LGND) will release its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, followed by a conference call at 8:30 a.m. ET to discuss the results and provide a business update. The biopharmaceutical company focuses on supporting the development of medicines through financing and licensing technologies, partnering with leading pharmaceutical companies, and leveraging its Captisol® and NITRICIL™ platform technologies. The article also provides detailed information on insider trading activity, institutional holdings, analyst ratings, and price targets for LGND.
Ligand Pharmaceuticals Announces Fourth Quarter and Full Year 2025 Financial Results Call Scheduled for February 26, 2026
Ligand Pharmaceuticals announced it will release its Q4 and full-year 2025 financial results on February 26, 2026, followed by a conference call at 8:30 a.m. ET to discuss the results and provide a business update. The biopharmaceutical company focuses on supporting the development of high-value medicines through financing and licensing technologies, partnering with leading pharmaceutical companies. The article also provides details on insider trading activity, revenue, hedge fund activity, analyst ratings, and price targets for LGND stock.
Impax Asset Management Group plc Sells 60,000 Shares of Ligand Pharmaceuticals Incorporated $LGND
Impax Asset Management Group plc has reduced its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 23.1%, selling 60,000 shares but still retaining over 200,000 shares valued at approximately $35.5 million. Analyst sentiment for LGND is positive, with a "Moderate Buy" consensus rating and a target price significantly above its current trading price. However, company insiders have been engaged in selling shares, indicating some internal divestment.
Villere ST Denis J & Co. LLC Has $49.59 Million Stock Position in Ligand Pharmaceuticals Incorporated $LGND
Villere ST Denis J & Co. LLC has reduced its stake in Ligand Pharmaceuticals Incorporated by 2.5%, now holding 279,950 shares valued at $49.59 million, representing 1.43% of the company. Despite this reduction, Ligand Pharmaceuticals remains Villere ST Denis J & Co. LLC's second-largest holding, accounting for 4.8% of its portfolio. The biotechnology company has received a "Moderate Buy" consensus rating from analysts, with an average price target of $239.33, and reported strong Q3 earnings with $3.09 EPS and 123% YoY revenue growth.
Stephens Investment Management Group LLC Sells 50,271 Shares of Ligand Pharmaceuticals Incorporated $LGND
Stephens Investment Management Group LLC reduced its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 8.3% in the third quarter, selling over 50,000 shares. Despite this, the firm still holds a significant position worth approximately $98.23 million. Ligand Pharmaceuticals reported strong earnings and revenue, with positive analyst sentiment, maintaining a "Moderate Buy" rating and a consensus price target indicating potential upside.
Ligand Pharmaceuticals Insiders Sell US$2.8m Of Stock, Possibly Signalling Caution
Over the past year, insiders at Ligand Pharmaceuticals (NASDAQ:LGND) sold US$2.8 million worth of stock, while purchasing US$1.2 million. This significant selling, particularly by Independent Director Jason Aryeh at a price below the current valuation and recent sales by CFO Octavio Espinoza, suggests a cautious outlook from insiders. Despite insiders holding 2.1% of the company, the net selling activities raise questions for potential investors.
Ligand Pharmaceuticals Incorporated $LGND Position Trimmed by Rice Hall James & Associates LLC
Rice Hall James & Associates LLC reduced its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 12.7% in Q3, now owning 294,490 shares valued at $52.17 million. Despite this trim, LGND remains its third-largest position, representing 2.8% of its investment portfolio. Ligand Pharmaceuticals reported strong earnings with an EPS of $3.09 and revenue of $86.89 million for the quarter, exceeding analyst expectations.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Moderate Buy" by Analysts
Ligand Pharmaceuticals (NASDAQ:LGND) has received a "Moderate Buy" consensus rating from analysts, with an average 1-year price target of approximately $239.33, following several raised price objectives. The company reported strong quarterly earnings, beating expectations with an EPS of $3.09 and revenue up 123% year-over-year, and has set optimistic FY2025 guidance. Insider activity shows recent stock sales by the CFO and a director, while institutional investors hold a significant majority of the shares.
Analysts’ Top Healthcare Picks: Ligand Pharma (LGND), MiMedx Group (MDXG)
This article highlights bullish sentiments from financial analysts on several healthcare stocks. Ligand Pharma (LGND) received a Strong Buy rating with a significant upside, supported by analysts from Craig-Hallum and Citi. MiMedx Group (MDXG) also earned a Strong Buy consensus, with a substantial potential upside, and was reaffirmed by Craig-Hallum.
Ligand Pharmaceuticals (NASDAQ: LGND) outlines Athira investment update and disclosure channels
Ligand Pharmaceuticals (NASDAQ: LGND) has filed an 8-K outlining its communication channels for material disclosures, including information about its private placement investment in Athira Pharma, Inc. The company encourages investors to follow its SEC filings, investor relations website, press releases, public calls, webcasts, and social media accounts (@Ligand_LGND on X and LinkedIn) for important updates. This filing emphasizes transparency and compliance with Regulation FD.
Ligand Pharmaceuticals Stock (LGND) Opinions on 2025 Investor Day and 2026 Guidance
Ligand Pharmaceuticals (LGND) held its 2025 Investor Day, sparking discussions on X about its updated 2026 revenue guidance of $245 million to $285 million and focus on royalty portfolio growth. The stock saw a slight uptick to $195.56, reflecting mixed investor sentiment. Insider trading activity shows 29 sales and no purchases in the last six months, while institutional investors have largely increased their positions.
Ligand Pharmaceuticals Stock (LGND) Opinions on 2025 Investor Day and 2026 Guidance
Ligand Pharmaceuticals' 2025 Investor Day in New York City generated discussion on X regarding its updated 2026 revenue guidance, projected between $245 million and $285 million, with a focus on royalty portfolio growth and strategic partnerships. The stock has seen a 57.96% increase over the past year, trading at $195.56, though some investors remain cautious. Insider trading shows 29 sales in the past 6 months, and institutional investors have largely increased their positions.
Ligand Pharmaceuticals Provides 2026 Revenue Guidance of $245 Million to $285 Million with Increased Royalty Revenue Outlook | LGND Stock News
Ligand Pharmaceuticals announced its 2026 revenue guidance, projecting between $245 million and $285 million, a 15% increase in core revenue growth. Royalty revenues are expected to rise 40% to $200-$225 million, driven by key products and supported by $1 billion in deployable capital. The company also anticipates core adjusted earnings per diluted share between $8.00 and $9.00 and foresees a long-term compound annual growth rate of at least 23% in royalty receipts.
Ligand Pharmaceuticals Incorporated $LGND Shares Bought by Legal & General Group Plc
Legal & General Group Plc increased its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 15.8% in Q2, acquiring 16,171 additional shares. This brings their total holding to 118,333 shares, valued at approximately $13.45 million. The biotechnology company reported strong quarterly earnings, beating analyst expectations, and has received multiple price target increases from brokerage firms.
Peering Into Ligand Pharmaceuticals Inc's Recent Short Interest
Ligand Pharmaceuticals Inc. (LGND) has seen a 7.23% decrease in its short interest, with 1.11 million shares now sold short, representing 6.8% of available shares. This decline in short interest suggests a potentially more bullish sentiment among investors for the company. Compared to its peers, Ligand Pharmaceuticals Inc. has less short interest on average.
Ligand (NASDAQ: LGND) to join UBS, Stifel, IDEAS conferences; fireside chat Nov 12
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that CEO Todd Davis and CFO Tavo Espinoza will participate in three investor conferences in November 2025. These include one-on-one meetings at the UBS Global Healthcare Conference on November 10, a fireside chat at the Stifel 2025 Healthcare Conference on November 12, and a presentation at the Southwest IDEAS 2025 Investor Conference on November 20. Investors interested in scheduling one-on-one meetings should contact their UBS or Stifel representatives.
Ligand Pharmaceuticals stock hits 52-week high at 186.46 USD By Investing.com - Investing.com UK
Ligand Pharmaceuticals stock reached a new 52-week high, trading at 186.46 USD. This achievement reflects a significant milestone for the company's market performance.
Ligand Pharmaceuticals Incorporated $LGND Shares Bought by Maryland State Retirement & Pension System - Defense World
Maryland State Retirement & Pension System has increased its stake in Ligand Pharmaceuticals Inc. Other institutional investors such as Maseco LLP, Opal Wealth Advisors LLC, GAMMA Investing LLC, Mirae Asset Global Investments Co. Ltd., and Exchange Traded Concepts LLC also made changes to their holdings. Analysts from Royal Bank Of Canada have raised their price target for Ligand Pharmaceuticals shares.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Rating of “Moderate Buy” by Analysts
Ligand Pharmaceuticals (NASDAQ:LGND) has received a "Moderate Buy" consensus rating from analysts, with several firms increasing their price targets and issuing "buy" or "outperform" ratings. The article also details recent insider stock sales and significant institutional investor activity, including new stakes and increased holdings in the company. Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and licensing biopharmaceutical assets globally.
Ligand Pharmaceuticals (LGND): Evaluating Valuation After FDA Green Light for Lasix ONYU’s At-Home Heart Failure Solution
Ligand Pharmaceuticals (LGND) has received FDA approval for Lasix ONYU, a drug-device product for chronic heart failure, leading to significant share price appreciation. The article evaluates LGND's valuation, presenting a narrative that suggests the stock is 2.9% undervalued with a fair value of $183.12, reflecting high market conviction in its future earnings and margin expansion. However, a contrasting view highlights a high price-to-sales ratio of 18.6x compared to the industry average of 4.7x, indicating potential valuation risk if growth falters.
Ligand Pharmaceuticals Announces FDA Approval of Lasix ONYU, Innovative Subcutaneous Delivery Device for Edema Treatment in Heart Failure Patients | LGND Stock News
Ligand Pharmaceuticals announced FDA approval for Lasix ONYU, a novel subcutaneous delivery device for furosemide, targeting edema in chronic heart failure patients. This innovative system, which uses Ligand's Captisol technology, allows for at-home treatment, offering a cost-effective alternative to hospital-administered IV diuretics. Lasix ONYU is expected to be available by late 2025 and aims to reduce hospitalizations for the millions affected by heart failure.
Ligand Pharmaceuticals Prices $400 Million Convertible Senior Notes Due 2030
Ligand Pharmaceuticals has priced $400 million in 0.75% convertible senior notes due 2030 in a private placement, with an option for initial purchasers to buy an additional $60 million. The company plans to use the net proceeds for convertible note hedge transactions, share repurchases, and general corporate purposes. This financial move aims to enhance flexibility, but also carries potential risks such as investor dilution and market volatility from hedging activities.
Ligand Pharmaceuticals Partner Pelthos Therapeutics Launches ZELSUVMI™ for Molluscum Contagiosum Treatment
Ligand Pharmaceuticals' partner Pelthos Therapeutics has launched ZELSUVMI™ (berdazimer) topical gel 10.3%, the first FDA-approved at-home treatment for molluscum contagiosum. This launch triggers a $5 million milestone payment to Ligand and establishes a 13% royalty on worldwide sales for the company. Ligand also now holds a 56% ownership stake in Pelthos Therapeutics, strengthening its position in this innovative treatment for a widespread viral skin condition.
Ligand Forms $50M Dermatology Powerhouse: First Home-Use Molluscum Treatment Coming
Ligand Pharmaceuticals has completed a merger between its subsidiary LNHC, Inc. and Channel Therapeutics' CHRO Merger Sub Inc., forming Pelthos Therapeutics. The new entity, trading as "PTHS" on NYSE American starting July 2, 2025, raised $50.1 million in equity capital. Pelthos will launch ZELSUVMI™, the first home-administered prescription treatment for Molluscum contagiosum infections, in July 2025, and Ligand will receive a 13% royalty on worldwide sales.
LGND Stock Price, News & Analysis
Ligand Pharmaceuticals (NASDAQ: LGND) operates a biopharma business model focused on generating revenue through royalties, licensing its Captisol® and NITRICIL™ technology platforms, and funding drug development programs. The company partners with major pharmaceutical corporations to leverage their development and commercialization capabilities, while Ligand retains economic rights. This strategy aims to offer investors diversified exposure to the biotech industry with an infrastructure-light approach.
Ligand Q1 2025 Earnings Coming May 8: Key Financial Results and Business Updates Expected Pre-Market
Ligand Pharmaceuticals (LGND) is set to announce its first-quarter 2025 financial results on Thursday, May 8, 2025, before U.S. markets open. The company will also host a conference call and webcast. Investors and interested parties can access the call via phone or webcast to hear the results and business updates.
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
Ligand Pharmaceuticals' subsidiary Pelthos Therapeutics will combine with Channel Therapeutics in a merger supported by $50 million in equity capital. The combined company, operating as Pelthos Therapeutics Inc. (ticker PTHS), will focus on commercializing ZELSUVMI™, an FDA-approved treatment for Molluscum contagiosum, and continue Channel's NaV 1.7 pain treatment programs. Ligand will retain a 13% royalty on worldwide sales of ZELSUVMI.
Ligand Pharma Enters $75M Agreement with Castle Creek
Ligand Pharmaceuticals has entered a $75 million Purchase and Sale Agreement with Castle Creek Biosciences and co-investors to fund the Phase 3 clinical study of D-Fi, a gene therapy for dystrophic epidermolysis bullosa (DEB). Ligand's investment of $50 million secures a high single-digit royalty on worldwide D-Fi sales and warrants to purchase Castle Creek shares. This collaboration highlights Ligand's strategy to invest in vital treatments and expand its portfolio of revenue-generating assets.
Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Share Price Matching Investor Opinion
Ligand Pharmaceuticals (NASDAQ:LGND) currently trades at a high P/E ratio of 48.9x, significantly above the U.S. market average. This premium valuation is attributed to the company's strong historical earnings growth of 105% last year, and particularly its robust future earnings outlook, with analysts forecasting 24% annual growth over the next three years, compared to an 11% market average. Investors are seemingly comfortable with the high P/E, expecting this superior growth to continue, thus suggesting the share price reflects positive investor sentiment regarding future earnings.
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences
Ligand Pharmaceuticals has finalized a $75 million royalty financing agreement with Castle Creek Biosciences to fund the Phase 3 clinical trial of D-Fi (FCX-007), a gene therapy for dystrophic epidermolysis bullosa (DEB). Ligand invested $50 million and led a syndicate including Paragon Biosciences, Valor Equity Partners, and XOMA Royalty Corporation, which contributed an additional $25 million, in exchange for a high-single digit royalty on D-Fi's worldwide sales. D-Fi is an injectable autologous gene-modified cell therapy aimed at treating the rare genetic skin disorder DEB, and has received multiple FDA designations, including Orphan Drug and Fast Track.
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
Ligand Pharmaceuticals launched Pelthos Therapeutics, a new biopharmaceutical company, to commercialize ZELSUVMI™ (berdazimer) topical gel, 10.3%, for molluscum contagiosum. Scott Plesha was appointed CEO of Pelthos, and ZELSUVMI, the first FDA-approved at-home topical treatment for molluscum, is expected to be available in late 2024. This move is part of Ligand's strategy to maximize the value of differentiated pharmaceutical assets by creating new entities with independent management and funding.
LGND: 2025 View Calls for 17% Topline Growth
Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) held its annual analyst day on December 10, 2024, forecasting 2025 revenues between $180 to $200 million, representing a 17% increase, and core adjusted EPS of $6.00 to $6.25. This growth is anticipated to be driven by strong royalty revenues from products like Filspari, Qarziba, Ohtuvayre, and Capvaxive, as well as increased Captisol sales to Gilead. The company detailed its investment strategy, financial capacity, and provided an updated valuation, setting a target price of $141 per share.
Ligand: Buy This Pharma And Get A Stake In Dozens Of Therapies (NASDAQ:LGND)
Ligand Pharmaceuticals (LGND) receives a "Buy" rating due to its strong liquidity, clean balance sheet, and robust Q3 2024 earnings performance, which beat expectations and raised prior guidance. The company's consistent financial performance and solid position make it an attractive investment choice. This article is the author's eighth on Ligand, noting a modest ~9.6% increase since the previous "Buy" recommendation in July 2024.
Todd Davis Bought 3.3% More Shares In Ligand Pharmaceuticals
Todd Davis, CEO & Director of Ligand Pharmaceuticals, recently purchased US$243k worth of company shares at US$97.39 per share, increasing his holding by 3.3%. This purchase contrasts with a trend of more insider selling than buying over the last year, with some insiders selling shares below the current market price. Despite the CEO's recent buy, the overall insider activity at Ligand Pharmaceuticals suggests caution for potential investors.
Ligand grows in cancer again with $100m Apeiron takeover
Ligand Pharmaceuticals has acquired Austria's Apeiron Biologics for $100 million, securing a royalty stream from the brain cancer drug Qarziba, used for high-risk neuroblastoma. This marks Ligand's second major acquisition in 2024, expanding its oncology portfolio. The deal also includes a potential additional payment to Apeiron shareholders and a $4 million investment in a spin-off company, invIOs, which is developing early-stage immuno-oncology projects.
Ligand taps Apeiron for a new royalty stream | ApexOnco - Clinical Trials news and analysis
Ligand Pharmaceuticals has acquired Apeiron for an upfront fee of $100 million, primarily to secure royalty streams from Apeiron's sole approved product, Qarziba, marketed in the EU for neuroblastoma. Ligand will also invest up to $4 million in inVIOs, Apeiron's spin-off for novel, higher-risk projects. This move aligns with Ligand's strategy of combining relatively safe bets with longer-shot investments in its oncology royalty portfolio, capitalized on companies seeking financing in the current market.
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI
Ligand Pharmaceuticals has launched Pelthos Therapeutics, a new biopharmaceutical company, to commercialize ZELSUVMI™ (berdazimer) topical gel for molluscum contagiosum. Scott Plesha has been appointed CEO of Pelthos, bringing over 30 years of industry experience. ZELSUVMI, the first FDA-approved at-home topical treatment for molluscum, is expected to be available in late 2024, with Ligand planning to commercialize it in partnership with a capital provider or strategic partner.
Watkins Advises Ligand Pharmaceuticals and OmniAb in Completion of Spin-Off and Business Combination
Latham & Watkins LLP advised Ligand Pharmaceuticals and OmniAb in the completion of a tax-free distribution and subsequent business combination. This transaction resulted in OmniAb, Inc. becoming an independent publicly traded company on Nasdaq under the ticker symbol “OABI.” The deal is notable as one of the first Reverse Morris Trust transactions combined with a deSPAC.
Avista Public Acquisition Corp. II (AHPA) Shareholders Approve Ligand Deal
Avista Public Acquisition Corp. II (AHPA) shareholders have approved the combination with Ligand Pharmaceuticals Incorporated to spin off its antibody discovery business, OmniAb, Inc. The deal was overwhelmingly approved despite a high 94.41% redemption rate, leaving OmniAb with approximately $95 million in net cash. The spin-off is on track to close on November 1st, with Ligand shareholders set to receive shares of OmniAb common stock.
